Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ).
Lumos Diagnostics has requested a trading halt in its shares on the ASX pending a market update on the U.S. Food and Drug Administration’s response to its CLIA waiver application for the FebriDx test. The halt is designed to help the company manage its continuous disclosure obligations and ensure all investors receive the update simultaneously.
Trading in Lumos securities will remain paused until the earlier of the start of normal trading on 27 March 2026 or the release of the pending announcement. The outcome of the FDA CLIA waiver process is likely to be significant for FebriDx’s U.S. deployment and could influence Lumos’s commercial prospects and valuation once trading resumes.
ASX Compliance has acknowledged the request, and Lumos has stated it expects to provide the announcement before trading restarts. The company has indicated it is unaware of any reasons the halt should not be granted or of any additional information required by the market at this stage.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.24 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a medical diagnostics company focused on point-of-care testing solutions. Its portfolio includes products such as FebriDx, which targets rapid detection of infectious diseases, positioning the company within the global in-vitro diagnostics and near-patient testing markets.
The company operates primarily through listings on the Australian Securities Exchange, using this platform to access capital and communicate regulatory and product milestones. Its activities are closely linked to regulatory pathways, particularly in the U.S., where FDA clearances and waivers are critical to commercial expansion and market penetration.
Average Trading Volume: 3,953,972
Technical Sentiment Signal: Buy
Current Market Cap: A$195.4M
For a thorough assessment of LDX stock, go to TipRanks’ Stock Analysis page.